|Last Update: 05/20/13 - 4:00 PM EDT|
|YTD Performance: 7.38%|
|Previous Close: $101.41|
|52 Week Range: $81.28 - $116.45|
|Oustanding Shares: 296,400,416|
|Market Cap: 30,057,966,187|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||15||15||19||18|
|Growth Rate (Year over Year)||12.09%||14.53%||14.80%||15.30%|
Jim Cramer looks at the overdone selloff in Allergan with 'Mad Money' Research Director Nicole Urken.
Focusing on near-term drug stock earnings is the wrong move.
TheStreet's Jim Cramer says Abbott Labs will benefit from growth in emerging markets and Glaxo will benefit from a "huge pipeline of approvals." The Action Alerts Plus portfolio recently bought Glaxo shares and added to their position in Abbott Labs.
AGN price target raised to $124, Citigroup said. Core franchises continue to deliver double digit growth. Buy rating.
Jim Cramer and his research associate Nicole Urken discuss Allergan's pipeline.
Portfolio manager David Peltier previews Wednesday's trading action.
Shares of AGN now seen reaching $100, Jefferies said. Estimates also raised on resiliency of model in the fourth quarter. Hold rating.
AGN was upgraded from Market Perform to Outperform, JMP Securities said. $135 price target. Company is seeing higher demand for Botox.
Remember when I said you want to buy a pullback? Take a good, long look at these two stellar names.